['psoriasis vulgaris']
['leo 90100 aerosol foam', 'aerosol foam vehicle', 'calcipotriol bdp gel', 'gel vehicle']

        Inclusion Criteria:

          -  Age 18 years or above

          -  Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and
             skin folds) involving 2-30% of the Body Surface Area (BSA)

          -  A Physician's Global Assessment of disease severity (PGA) of at least mild on trunk
             and limbs

          -  A modified Psoriasis Area Severity Index (PASI) score of at least 2 on the trunk and
             limbs.

        Exclusion Criteria:

          -  Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis

          -  Systemic treatment with biological therapies, whether marketed or not, with a possible
             effect on psoriasis vulgaris within the following time periods prior to randomisation:

               -  etanercept - within 4 weeks prior to randomisation

               -  adalimumab, infliximab - within 8 weeks prior to randomisation

               -  ustekinumab - within 16 weeks prior to randomisation

               -  other products - within 4 weeks/5 half-lives prior to randomisation (whichever is
                  longer)

          -  Systemic treatment with all other therapies with a possible effect on psoriasis
             vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other
             immunosuppressants within 4 weeks prior to randomisation)

          -  Subjects who have received treatment with any non-marketed drug substance (i.e. a drug
             which has not yet been made available for clinical use following registration) within
             4 weeks/5 half-lives (whichever is longer) prior to randomisation.

          -  Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to
             randomisation

          -  Ultraviolet B (UVB) therapy within 2 weeks prior to randomisation

          -  Topical anti-psoriatic treatment on the trunk and limbs (except for emollients) within
             2 weeks prior to randomisation

          -  Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D
             analogues or prescription shampoos within 2 weeks prior to randomisation

          -  Females who are pregnant, wishing to become pregnant during the trial or are
             breastfeeding
      